Hepatitis Central

• Previous: Japanese Researchers Make Progress
• Main
• Next: Your Results May Vary For HCV Treatment

More HCV Treatment News Coverage

October 26, 2005

Printer-friendly version

The Los Angeles Times is one of the largest daily newspapers in the U.S. Their interest in HCV is indicative of a growing awareness of the extent of the disease in this country.

The article clearly focuses on the hope of safer, more effective treatments than what is now available.

Science & Medicine | Los Angeles Times Examines Study Results of Three Experimental Hepatitis C Treatments

[Oct 25, 2005]

More than 24 hepatitis C treatments currently are in development, and at least three drugs are demonstrating the potential to prevent the virus from replicating, the Los Angeles Times reports. "These drugs are more potent and have much less side effects" than treatments that currently are available, Eugene Schiff, director of the Center for Liver Diseases at the University of Miami, said.

One drug, called valopicitabine -- which is manufactured by Cambridge, Mass.-based Idenix Pharmaceuticals and is currently in more advanced clinical trials than other experimental hepatitis C therapies -- works by blocking the action of RNA polymerase, an enzyme the virus needs to replicate. In a study of 79 patients conducted last year, the once-a-day pill reduced hepatitis C viral levels by up to 90% after two weeks of treatment, even though 87% of the trial's participants had received previous treatments that failed to reduce their viral loads. The interim results of another valopicitabine trial -- which involved 190 hepatitis C patients not helped by conventional treatment regimens -- are scheduled to be released in November. Preliminary results of that trial show a decrease in viral reproduction, according to the Times. Nathaniel Brown, chief medical officer at Idenix, said that valopicitabine likely will be part of a combination therapy, "but we're in a race against time because the number of people with advanced disease is steadily increasing."

Two other experimental hepatitis C drugs recently have completed early stage clinical trials: SCH-503034, made by Schering-Plough, and VX-950, made by Cambridge, Mass.-based Vertex. Both treatments target the protease enzyme, which the virus uses to reproduce. Results from a Shering study on SCH-503034 are expected to be released in November, and Shering liver expert Janice Albrecht said that the decrease in viral levels was "significant." A study conducted this year of VX-950 involving 34 volunteers showed that after two weeks of treatment, the medication proved 250 times as powerful as conventional medication in reducing hepatitis C levels. Researchers are planning additional studies for both drugs (Marsa, Los Angeles Times, 10/24).

Posted by Ralph at October 26, 2005 9:57 AM